MedTrace Logo

Differential Immune Effects of Natalizumab

NCT00859482 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2009-03-11

No results posted yet for this study

Summary

Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade of VLA-4 with natalizumab may not only interfere with autoimmunological processes but also with central nervous system (CNS) immune surveillance.

Conditions

  • Multiple Sclerosis, Relapsing Remitting

Sponsors & Collaborators

  • Cantonal Hospital of St. Gallen

    lead OTHER

Principal Investigators

  • Norman Putzki, MD · KSSG, 9007 St. Gallen, Switzerland

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-07-31
Completion
2007-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00859482 on ClinicalTrials.gov